ArticleBMC microbiology2025
Evolution and high transferability of an IncN/FII plasmid harboring bla
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasmid encodedBiofilm · 2026Article
- Emergence of hypervirulent Klebsiella pneumoniae ST111 with a novel virulence plasmid causing pyogenic liver abscess.BMC microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveCarbapenem-resistant Enterobacteriaceae (CRE), primarily driven by plasmid-mediated KPC enzymes, pose a major clinical threat, and resistance to ceftazidime-avibactam (CAZ-AVI) is emerging. This study aimed to investigate the emergence of the blaKPC-33 variant in Enterobacter intestinihominis (E. intestinihominis) following ceftazidime (CAZ) treatment and to explore the evolution of blaKPC-2 under CAZ pressure and the mechanisms of resistance gene dissemination.
methodsTwo E. intestinihominis isolates, JNQH617 and JNQH618, were obtained from the same urine sample of an ICU patient undergoing CAZ therapy. We employed a combination of antimicrobial susceptibility testing, whole-genome sequencing (WGS), pulsed-field gel electrophoresis (PFGE), conjugation assays, and CRISPR/Cas9-based plasmid curing to explore the genetic basis of CAZ-AVI resistance and the roles of conjugative plasmids in gene dissemination.
resultsStrains JNQH617 and JNQH618 belong to sequence type 78 (ST78), harbored KPC-2 and KPC-33 respectively. Both variants were located on highly transmissible IncN/FII hybrid plasmids (nearly 100% transfer efficiency). In vitro selection experiments confirmed that prolonged exposure to CAZ alone could drive the emergence of novel KPC variants, which conferred resistance to CAZ-AVI. However, this mutational resistance could not be selected in K. pneumoniae species complex (KpSC), Serratia marcescens and Citrobacter freundii strains. CRISPR/Cas9-based dual-sgRNA strategy enables complete curing of the hybrid IncN/FII plasmid. Interestingly, the presence of an additional IncFIB/FII plasmid significantly enhanced the IncN/FII plasmid transfer efficiency.
conclusionThis study reports the first identification of a blaKPC-33–producing E. intestinihominis strain. Its emergence occurred independently of CAZ-AVI therapy and is likely attributable to selective pressure from CAZ exposure. The high conjugative efficiency of the blaKPC-carrying IncN/FII plasmid underscores the risk of rapid dissemination of carbapenem and CAZ-AVI resistance. These findings highlight the importance of further investigating plasmid-plasmid and plasmid-host interactions, which may play crucial roles in the evolution and transmission of antimicrobial resistance determinants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.